BridgeBio Pharma (BBIO) Amortizatization of Intangibles (2018 - 2025)

BridgeBio Pharma (BBIO) has 8 years of Amortizatization of Intangibles data on file, last reported at $27.5 million in Q2 2025.

• For the quarter ending Q2 2025, Amortizatization of Intangibles rose 1546.58% year-over-year to $27.5 million; the trailing twelve-month figure through Jun 2025 stood at $65.2 million (up 713.81% YoY), and the FY2024 full-year result was $15.8 million, up 76.97% from the prior year.
• Amortizatization of Intangibles rose to $27.5 million in Q2 2025, from $25.6 million in the prior quarter.
• In the past five years, Amortizatization of Intangibles ranged from a high of $27.5 million in Q2 2025 to a low of $1.2 million in Q1 2021.
• A 5-year average of $5.1 million and a median of $2.1 million in 2022 frame the typical range for Amortizatization of Intangibles.
• Across the five-year window, Amortizatization of Intangibles sank 73.95% in 2021 and jumped 1546.58% in 2025, its largest moves.
• Tracing BBIO's Amortizatization of Intangibles over 5 years: stood at $1.8 million in 2021, then grew by 19.92% to $2.1 million in 2022, then climbed by 3.9% to $2.2 million in 2023, then surged by 374.76% to $10.4 million in 2024, then soared by 165.0% to $27.5 million in 2025.
• Business Quant data shows BBIO's Amortizatization of Intangibles at $27.5 million in Q2 2025, $25.6 million in Q1 2025, and $10.4 million in Q4 2024.